Zacks Research Predicts Higher Earnings for Veeva Systems

Veeva Systems Inc. (NYSE:VEEV) – Stock analysts at Zacks Research increased their Q1 2026 earnings per share (EPS) estimates for shares of Veeva Systems in a research note issued to investors on Wednesday, March 26th. Zacks Research analyst R. Department now forecasts that the technology company will post earnings per share of $1.21 for the quarter, up from their previous estimate of $1.08. The consensus estimate for Veeva Systems’ current full-year earnings is $4.35 per share. Zacks Research also issued estimates for Veeva Systems’ FY2026 earnings at $5.07 EPS, Q3 2027 earnings at $1.42 EPS, Q4 2027 earnings at $1.43 EPS, FY2027 earnings at $5.53 EPS and FY2028 earnings at $6.79 EPS.

A number of other equities analysts have also recently weighed in on VEEV. Evercore ISI lifted their price target on Veeva Systems from $220.00 to $245.00 and gave the stock an “in-line” rating in a research note on Friday, December 6th. Mizuho initiated coverage on shares of Veeva Systems in a research note on Wednesday, December 4th. They issued an “outperform” rating and a $275.00 price target on the stock. Canaccord Genuity Group raised their price objective on shares of Veeva Systems from $210.00 to $270.00 and gave the company a “hold” rating in a research report on Friday, December 6th. Needham & Company LLC restated a “buy” rating and set a $270.00 target price on shares of Veeva Systems in a report on Thursday, March 6th. Finally, Morgan Stanley boosted their price objective on shares of Veeva Systems from $195.00 to $201.00 and gave the stock an “underweight” rating in a research note on Thursday, March 6th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, Veeva Systems currently has a consensus rating of “Moderate Buy” and an average price target of $256.52.

Veeva Systems Stock Performance

Shares of NYSE:VEEV opened at $227.74 on Monday. The stock has a market capitalization of $37.05 billion, a price-to-earnings ratio of 56.23, a PEG ratio of 1.89 and a beta of 0.88. The company has a 50 day moving average price of $232.01 and a 200 day moving average price of $223.02. Veeva Systems has a 1-year low of $170.25 and a 1-year high of $258.93.

Institutional Investors Weigh In On Veeva Systems

Several institutional investors and hedge funds have recently made changes to their positions in the company. Principal Financial Group Inc. lifted its position in Veeva Systems by 138.9% during the 3rd quarter. Principal Financial Group Inc. now owns 2,179,284 shares of the technology company’s stock worth $457,366,000 after buying an additional 1,267,061 shares in the last quarter. Algert Global LLC grew its stake in shares of Veeva Systems by 64.0% during the third quarter. Algert Global LLC now owns 2,254 shares of the technology company’s stock worth $473,000 after purchasing an additional 880 shares during the period. D.A. Davidson & CO. increased its stake in shares of Veeva Systems by 2.5% in the 3rd quarter. D.A. Davidson & CO. now owns 5,630 shares of the technology company’s stock valued at $1,182,000 after acquiring an additional 136 shares during the last quarter. Townsquare Capital LLC raised its holdings in Veeva Systems by 35.7% in the third quarter. Townsquare Capital LLC now owns 4,762 shares of the technology company’s stock worth $999,000 after purchasing an additional 1,253 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Veeva Systems by 17.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 77,653 shares of the technology company’s stock worth $16,297,000 after buying an additional 11,433 shares during the period. Institutional investors and hedge funds own 88.20% of the company’s stock.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.